HC Wainwright Reiterates “Buy” Rating for Inventiva (NASDAQ:IVA)

Inventiva (NASDAQ:IVA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $13.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 343.53% from the company’s current price.

Separately, TD Cowen initiated coverage on Inventiva in a research note on Friday, February 21st. They set a “buy” rating and a $10.00 price target for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.60.

Inventiva Price Performance

Shares of NASDAQ IVA opened at $2.93 on Friday. Inventiva has a 1 year low of $1.53 and a 1 year high of $3.98. The firm has a 50-day simple moving average of $2.70 and a two-hundred day simple moving average of $2.48.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.